转移性肝癌的综合治疗策略

肝脏是结直肠癌血行转移的主要靶器官,且结直肠癌肝转移是影响结直肠癌患者预后的重要因素。根治性的肝段或肝叶切除是目前治疗肝转移的"金标准",但术后5年生存率仅为37%～44%,且只有10%～20%的患者适合手术治疗。其他非手术治疗方案如局部治疗(射频消融术等)、化疗联合分子靶向药物治疗以及基因治疗等正日益受到关注。

Multidisciplinary Management of Colorectal Liver Metastases

Liver is one of the leading hematogenous metastases in patients with colorectal cancer,and the colorectal liver metastases(CRLM)are the main prognostic factor.Although liver resection is the gold standard of CRLM,the 5-year survival rate ranges from 37% to 44%,and only 10%-20% of patients with CRLM are found resectable.Currently,non-surgical treatment,such as local treatment(radiofrequency ablation),chemotherapy combined with molecular targeted therapy and gene therapy are arousing more attention.